Domov › Skvamóznocelulárny karcinóm hlavy a krku › Massachusetts › Boston
Klinické štúdie Skvamóznocelulárny karcinóm hlavy a krku v meste Boston, MA
40 štúdií pre Skvamóznocelulárny karcinóm hlavy a krku hľadá účastníkov v zariadeniach v meste Boston a okolí (do cca 30 míľ). Otvorte štúdiu a zistite, kto sa môže zapojiť a ako kontaktovať tím.
Oficiálny text štúdie (anglicky)
Hľadáte účastníkov do štúdie? Zvýraznite ju na začiatku tejto stránky – $99 na 30 dní →
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Prebieha náborFáza 1
- Massachusetts General Hospital, Boston
FORTIFI-HN01: A Study of Ficerafusp Alfa (BCA101) or Placebo in Combination With Pembrolizumab in First-Line PD-L1-pos, R or M HNSCC
Prebieha náborFáza 2/3
- Site #0131, Boston
- Site#0101, Boston
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Prebieha náborFáza 1
- Exelixis Clinical Site #7, Boston
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Prebieha náborFáza 3
- Boston Medical Center, Boston
A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors
Prebieha náborFáza 1
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Prebieha náborFáza 1
- Research Site, Boston
- Research Site, Boston
A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck Cancer
Prebieha náborFáza 3
- Dana Farber Cancer Institute, Boston
A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer
Prebieha náborFáza 1/2
- Dana Farber Cancer Institute, Boston
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
Prebieha náborFáza 3
- Boston Medical Center, Boston
A Study of JNJ-90301900 in Combination With Chemoradiation Therapy in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma
Prebieha náborFáza 1
- Boston Medical Center, Boston
Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis
Prebieha náborFáza 1/2
- Tufts Medical Center, Boston
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
Prebieha náborFáza 2
- Tufts Medical Center, Boston
Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
Prebieha náborFáza 1
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Prebieha náborFáza 1/2
- Massachusetts General Hospital, Boston
Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
Prebieha náborFáza 2
- Tufts Medical Center, Boston
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Prebieha náborFáza 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
ADCE-T02, a Tissue Factor Targeted Antibody-Drug Conjugate, in Patients With Selected Advanced Solid Tumours
Prebieha náborFáza 1
- Massachusetts General Hospital, Boston
A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Prebieha náborObservačná štúdia
- Dana Farber Cancer Institute, Boston
PD-L1 t-haNK, NAI IL-15sa and Cetuximab for Recurrent, Metastatic HNSCC
Prebieha náborFáza 2
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
Prebieha náborFáza 1
- Normunity Investigational Site, Boston
- Normunity Investigational Site, Boston
Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
Prebieha náborFáza 2
- Boston Medical Center, Boston
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
Prebieha náborFáza 1/2
- Massachusetts General Hospital - Dana Farber, Boston
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Prebieha náborFáza 1
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
PDT For Induction Therapy For Head And Neck Cancer
Prebieha náborFáza 2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Prebieha náborFáza 1/2
- Massachusetts General Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Prebieha náborFáza 1
- Massachusetts General Hospital, Boston
- Brigham & Women's Hospital, Boston
- Beth Israel Deaconess Medical Center,East Campus Research Pharmacy, Boston
- a 2 ďalších
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
Prebieha náborFáza 1/2
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCC
Prebieha náborFáza 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Prebieha náborFáza 1
- Beth Israel Deaconess Medical Center /ID# 252009, Boston
- Dana-Farber Cancer Institute /ID# 249642, Boston
A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
Prebieha náborFáza 3
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
Prebieha náborFáza 1/2
- Dana-Farber Cancer Institute, Boston
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Prebieha náborFáza 1
- Dana Farber Cancer Institute, Boston
Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC
Prebieha náborFáza 2
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
Prebieha náborSkorá fáza 1
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
Prebieha náborFáza 1/2
- Massachusetts General Hospital, Boston
- Dana Farber Cancer Institute, Boston
A Study to Evaluate TROP2 ADC LCB84 Single Agent and in Combination With an Anti-PD-1 Ab in Advanced Solid Tumors
Prebieha náborFáza 1/2
- Dana Farber Cancer Institute, Boston
Study of Safety and Tolerability of BCA101 Monotherapy and in Combination Therapy in Patients With EGFR-driven Advanced Solid Tumors
Prebieha náborFáza 1
- Dana Farber/Partners Cancer Care Inc, Boston
Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck
Prebieha náborObservačná štúdia
- Massachusetts Eye and Ear, Boston
Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067
Prebieha náborFáza 1/2
- Massachusetts General Hospital, Boston
Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors
Prebieha náborFáza 2
- Dana Farber Cancer Institute, Boston
Štúdie Skvamóznocelulárny karcinóm hlavy a krku v iných mestách
- Houston, TX47 štúdií
- Los Angeles, CA42 štúdií
- New York City, NY39 štúdií
- Nashville, TN39 štúdií
- St. Louis, MO28 štúdií
- Arlington, VA26 štúdií
- Philadelphia, PA26 štúdií
- Chicago, IL26 štúdií
- Atlanta, GA24 štúdií
- San Antonio, TX22 štúdií
- New Haven, CT22 štúdií
- Pittsburgh, PA22 štúdií
Iné štúdie v Boston
- Rakovina prsníka112 štúdií
- Nemalobunkový karcinóm pľúc90 štúdií
- Rakovina (všetky typy)85 štúdií
- Metastatická rakovina63 štúdií
- Kolorektálny karcinóm63 štúdií
- Rakovina pľúc62 štúdií
- Rakovina vaječníkov61 štúdií
- Rakovina prostaty59 štúdií
- Depresia52 štúdií
- Rakovina endometria50 štúdií
- Srdcové zlyhanie44 štúdií
- Akútna myeloidná leukémia44 štúdií
Z ClinicalTrials.gov, dáta načítané 6. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.